Summary
The pharmacokinetics of orally administered ranitidine were studied in 17 male patients with chronic duodenal ulceration. The patients were divided into 2 groups, 10 responders and 7 nonresponders, on the basis of their endoscopic response to ranitidine treatment. The 10 responders were studied both after a single 150 mg dose (SD) and after multiple dosing (MD) with ranitidine 150 mg twice daily for 4 weeks. The area under the curve (AUC) and maximum concentration (Cmax) were significantly higher (p<0.01 andp<0.05, respectively) after MD than after SD, but the half-life (t1/2) and minimum concentration (Cmin) 12 h postdosing did not differ. The non-responders were studied after MD only and their pharmacokinetic characteristics were compared with those of responders. No differences between the 2 groups were found. However, 2 non-responders had particularly low plasma ranitidine levels and high acid output. Such patients may need larger doses of ranitidine for adequate suppression of gastric acid. Five patients (4 responders and 1 non-responder) received ranitidine 20 mg i.v. The drug followed a two-compartment model, with mean values for t1/2β, volume of distribution steady-state and total plasma clearance of 80 min, 701 and 680 ml/min, respectively. The oral bioavailability of ranitidine in these 5 patients showed wide variation (27–76%; mean 51%).
Similar content being viewed by others
References
Daly MJ, Humphray JM, Stables R (1980) Inhibition of gastric acid secretion in the dog by the H2-receptor antagonists, ranitidine, cimetidine and metiamide. Gut 21: 408–412
Daly MJ, Humphray JM, Stables R (1981) Some in vitro and in vivo actions of the new histamine H2-receptor antagonist, ranitidine. Br J Pharmacol 72: 49–54
Berstad A, Kett K, Aadland E, Carlsen E, Frislid K, Saxhaug K, Kruse-Jensen A (1980) Treatment of duodenal ulcer with ranitidine, a new histamine H2 receptor antagonist. Scand J Gastroenterol 15: 637–639
Moshal MG, Spitaels JM, Kahn F (1981) A double-blind endoscopically controlled trial of ranitidine in a high incidence area. Scand J Gastroenterol 16 [Suppl 69]: 129–131
Dobrilla G, Barbara L, Bianchi Porro G, Felder M, Mazzacca G, Miglioli L, Pera A, Petrill M, Sabbatini F, Verme G (1981) Placebo controlled studies with ranitidine in duodenal ulcer. Scand J Gastroenterol 16 [Suppl 69]: 101–105
Langman MJS, Henry DA, Bell GD, Burnham WR, Ogilvy A (1980) Cimetidine and ranitidine in duodenal ulcer. Br Med J 281: 473–474
Boyd EJS, Peden NR, Browning MCK, Saunders JHB, Wormsley KG (1981) Clinical and endocrine aspects of treatment with ranitidine. Scand J Gastroenterol 16 [Suppl 69]: 81–83
Henry DA, MacDonald JA, Kitchingman G, Bell GD, Langman MJS (1980) Cimetidine and ranitidine: a comparison of effects on hepatic drug metabolism. Br Med J 281: 775–777
Marks IN, Wright JP, Denyer M, Hatfield A, Girdwood AH, Lucke W (1982) Ranitidine heals duodenal ulcers. S Afr Med J 61: 152–154
Carey PF, Martin LE (1979) A high performance liquid chromatography method for the determination of ranitidine in plasma. J Liquid Chromatogr 2 [9]: 1291–1303
Gibaldi M, Perrier D (1975) Pharmacokinetics. Marcel Dekker, New York
Peden NR, Richards DA, Saunders JHB, Wormsley KB (1979) Pharmacologically effective plasma concentrations of ranitidine. Lancet 2: 199–200
Garg DC, Weidler DJ, Baltoclano N, Eshelman FN (1981) Pharmacokinetics of ranitidine, a new histamine H2-receptor blocker (Abstract). Clin Pharmacol Ther 29 [2]: 247–248
Louis WJ, Mihaly GW, Hanson RG, Anderson A, McNeel JJ, Yeomans ND, Smallwood RA (1981) Pharmacokinetic and gastric secretory studies of ranitidine in man. Scand J Gastroenterol 16 [Suppl 69]: 11–15
Woodings EP, Dixon GT, Harrison C, Carey P, Richards DA (1980) Ranitidine — a new H2-receptor antagonist. Gut 21: 187–191
Veng Pedersen, Miller R (1980) Pharmacokinetics and bioavailability of cimetidine in humans. J Pharm Sci 69 [4]: 394–398
Somogyi A, Rohner HG, Gugler R (1980) Pharmacokinetics and bioavailability of cimetidine in gastric and duodenal ulcer patients. Clin Pharmacokinet 5: 84–94
Moshal MG, Spitaels KM, Kahn F, Mason J, Naidoo V, Schlemmer L (1982) Factors affecting duodenal ulcer healing. S Afr Med J 61: 202–206
Korman MG, Hansky J, Merrett AC, Schmidt GT (1981) Ranitidine in duodenal ulcer: healing rate and effect of smoking. Gastroenterology 80: 1197
Roberts DM, Wilson JA, Ratcliffe GE, Waring AJ, Reilly MJ, Lloyd JS (1982) Clinical trial of ranitidine in the treatment of peptic ulcer. Br J Clin Pract 36 [1]: 9–12
McFadyen ML, Folb PI, Marks IN, Wright JP, Lucke W (1981) The pharmacokinetics of ranitidine in patients with chronic duodenal ulceration. Scand J Gastroenterol 16 [Suppl 69]: 109–112
Binder HJ, Cocco A, Crossley RJ, Finkelstein W, Font R, Friedman G et al. (1978) Cimetidine in the treatment of duodenal ulcer. A multicentre double blind study. Gastroenterology 74: 380–388
Rune SJ, Hesselfeldt P, Larsen NE (1979) Clinical and pharmacological effectiveness of cimetidine in duodenal ulcer patients. Scand J Gastroenterol 14: 489–492
Author information
Authors and Affiliations
Additional information
Deceased 14 October, 1981
Rights and permissions
About this article
Cite this article
McFadyen, M.L., Folb, P.I., Miller, R. et al. The pharmacokinetics of ranitidine in patients with chronic duodenal ulceration: A comparison of responders and non-responders. Eur J Clin Pharmacol 24, 441–447 (1983). https://doi.org/10.1007/BF00609883
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00609883